{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:21:47Z","timestamp":1769599307828,"version":"3.49.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT). It has been proposed that tumor necrosis factor \u03b1 (TNF-\u03b1) blockade with infliximab may be an effective treatment for severe (grades III-IV) GVHD. We determined if infliximab use in this high-risk population was associated with an additional increased risk of non-Candida invasive fungal infections (IFIs). Records of the 2000-2001 HSCT cohort at our institution were reviewed. Fifty-three (20%) of 264 evaluable patients developed severe GVHD and 11 of these 53 (21%) received infliximab for treatment. Proven or probable IFI was documented in 10 (19%) of 53 patients with severe GVHD (incidence rate of 0.99 cases\/1000 GVHD patient-days). When stratified by infliximab use, 5 of 11 infliximab recipients developed an IFI (6.78 cases\/1000 GVHD patient-days), compared with 5 of 42 IFI cases among nonrecipients (0.53 cases\/1000 GVHD patient-days). In a time-dependent Cox regression model among patients with severe GVHD, the adjusted IFI hazard ratio of infliximab exposure was 13.6 (P = .004; 95% CI, 2.29-80.2). We conclude that infliximab administration is associated with a significantly increased risk of non-Candida IFI in HSCT recipients with severe GVHD disease. Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used.<\/jats:p>","DOI":"10.1182\/blood-2003-01-0267","type":"journal-article","created":{"date-parts":[[2003,7,15]],"date-time":"2003-07-15T00:20:59Z","timestamp":1058228459000},"page":"2768-2776","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":163,"title":["Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study"],"prefix":"10.1182","volume":"102","author":[{"given":"Francisco M.","family":"Marty","sequence":"first","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Fahey","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases and the Hematopoietic Stem-Cell Transplantation Service, Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021218361702700_REF1","doi-asserted-by":"crossref","unstructured":"Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97: 855-864.","DOI":"10.1046\/j.1365-2141.1997.1112925.x"},{"key":"2020021218361702700_REF2","doi-asserted-by":"crossref","unstructured":"Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev. 2000;14: 190-204.","DOI":"10.1054\/blre.2000.0137"},{"key":"2020021218361702700_REF3","doi-asserted-by":"crossref","unstructured":"Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175: 1459-1466.","DOI":"10.1086\/516480"},{"key":"2020021218361702700_REF4","doi-asserted-by":"crossref","unstructured":"Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 1994;84: 1328-1332.","DOI":"10.1182\/blood.V84.4.1328.1328"},{"key":"2020021218361702700_REF5","unstructured":"Cohen J. Cytokines as mediators of graft-versus-host disease. Bone Marrow Transplant. 1988;3: 193-197."},{"key":"2020021218361702700_REF6","doi-asserted-by":"crossref","unstructured":"Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75: 1011-1016.","DOI":"10.1182\/blood.V75.4.1011.1011"},{"key":"2020021218361702700_REF7","doi-asserted-by":"crossref","unstructured":"Symington FW, Pepe MS, Chen AB, Deliganis A. Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation. 1990;50: 518-521.","DOI":"10.1097\/00007890-199009000-00033"},{"key":"2020021218361702700_REF8","doi-asserted-by":"crossref","unstructured":"Shalaby MR, Fendly B, Sheehan KC, Schreiber RD, Ammann AJ. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation. 1989;47: 1057-1061.","DOI":"10.1097\/00007890-198906000-00028"},{"key":"2020021218361702700_REF9","doi-asserted-by":"crossref","unstructured":"Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with in flixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000; 12: 582-587.","DOI":"10.1097\/00001622-200011000-00011"},{"key":"2020021218361702700_REF10","unstructured":"Couriel DR, Hicks K, Ippoliti C, et al. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update [abstract]. Blood. 2000;96: 400a."},{"key":"2020021218361702700_REF11","doi-asserted-by":"crossref","unstructured":"Lee SJ, Zahrieh D, Alyea EP, et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002;100: 2697-2702.","DOI":"10.1182\/blood-2002-03-0984"},{"key":"2020021218361702700_REF12","unstructured":"Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15: 825-828."},{"key":"2020021218361702700_REF13","doi-asserted-by":"crossref","unstructured":"Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34: 7-14.","DOI":"10.1086\/323335"},{"key":"2020021218361702700_REF14","unstructured":"Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and action of adrecortical hormones. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001: 1649-1677."},{"key":"2020021218361702700_REF15","unstructured":"Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. Gaithersburg, MD: Aspen; 2000."},{"key":"2020021218361702700_REF16","unstructured":"Rothman KJ. Epidemiology: An Introduction. New York, NY: Oxford University Press; 2002."},{"key":"2020021218361702700_REF17","unstructured":"Allison PD. Estimating Cox regression models. In: Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995: 111-184."},{"key":"2020021218361702700_REF18","doi-asserted-by":"crossref","unstructured":"Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95: 83-89.","DOI":"10.1182\/blood.V95.1.83"},{"key":"2020021218361702700_REF19","doi-asserted-by":"crossref","unstructured":"Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118: 201-210.","DOI":"10.7326\/0003-4819-118-3-199302010-00009"},{"key":"2020021218361702700_REF20","unstructured":"Levine M, Haslam D, Walter S, et al. Harm. In: Guyatt G, Rennie D, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Press; 2002: 81-100."},{"key":"2020021218361702700_REF21","doi-asserted-by":"crossref","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340: 1398-1405.","DOI":"10.1056\/NEJM199905063401804"},{"key":"2020021218361702700_REF22","doi-asserted-by":"crossref","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343: 1594-1602.","DOI":"10.1056\/NEJM200011303432202"},{"key":"2020021218361702700_REF23","unstructured":"Abbas AK, Lichtman AH, Pober JS. Cytokines. In: Cellular and Molecular Immunology. 4th ed. Philadelphia, PA: Saunders; 2000: 235-269."},{"key":"2020021218361702700_REF24","doi-asserted-by":"crossref","unstructured":"Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis. 1995;172: 1554-1560.","DOI":"10.1093\/infdis\/172.6.1554"},{"key":"2020021218361702700_REF25","doi-asserted-by":"crossref","unstructured":"Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002;21: 161-172.","DOI":"10.1007\/s10096-002-0699-z"},{"key":"2020021218361702700_REF26","doi-asserted-by":"crossref","unstructured":"Song XY, Fox F, Gallo MA, et al. Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation. J Infect Dis. 2002;185: 204-213.","DOI":"10.1086\/338451"},{"key":"2020021218361702700_REF27","doi-asserted-by":"crossref","unstructured":"Allendoerfer R, Deepe GS. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol. 1998;160: 6072-6082.","DOI":"10.4049\/jimmunol.160.12.6072"},{"key":"2020021218361702700_REF28","doi-asserted-by":"crossref","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098-1104.","DOI":"10.1056\/NEJMoa011110"},{"key":"2020021218361702700_REF29","doi-asserted-by":"crossref","unstructured":"Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46: 2565-2570.","DOI":"10.1002\/art.10583"},{"key":"2020021218361702700_REF30","doi-asserted-by":"crossref","unstructured":"Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992;79: 3362-3368.","DOI":"10.1182\/blood.V79.12.3362.bloodjournal79123362"},{"key":"2020021218361702700_REF31","unstructured":"Redei I, Knoche J, Tanner AR, et al. Salvage therapy with infliximab for patients with severe acute and chronic GVHD [abstract]. Blood. 2001; 98: 399a."},{"key":"2020021218361702700_REF32","unstructured":"Magalhaes-Silverman M, Lee CK, Hohl R, Becker A, Gingrich R. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab [abstract]. Blood. 2001;98: 359b."},{"key":"2020021218361702700_REF33","doi-asserted-by":"crossref","unstructured":"Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human\/mouse antiTNFalpha antibody. Bone Marrow Transplant. 2001;28: 47-49.","DOI":"10.1038\/sj.bmt.1703094"},{"key":"2020021218361702700_REF34","doi-asserted-by":"crossref","unstructured":"Rivkina AM, Stump LS. Infliximab in graft-versus-host disease. Am J Health Syst Pharm. 2002;59: 1271-1275.","DOI":"10.1093\/ajhp\/59.13.1271"},{"key":"2020021218361702700_REF35","doi-asserted-by":"crossref","unstructured":"Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26: 781-803.","DOI":"10.1086\/513943"},{"key":"2020021218361702700_REF36","doi-asserted-by":"crossref","unstructured":"Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 1999;28: 322-330.","DOI":"10.1086\/515116"},{"key":"2020021218361702700_REF37","doi-asserted-by":"crossref","unstructured":"Basara N, Blau IW, Willenbacher W, Kiehl MG, Fauser AA. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant. 2000;25(suppl 2): S12-S15.","DOI":"10.1038\/sj.bmt.1702345"},{"key":"2020021218361702700_REF38","doi-asserted-by":"crossref","unstructured":"Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001;112: 820-823.","DOI":"10.1046\/j.1365-2141.2001.02582.x"},{"key":"2020021218361702700_REF39","unstructured":"Srinivasan R, Geller N, Chakrabarti S, et al. High response rate and improved survival in patients with steroid-refractory acute graft-vs-host disease (SRGVHD) with daclizumab with or without infliximab [abstract]. Blood. 2002;100: 173a."},{"key":"2020021218361702700_REF40","doi-asserted-by":"crossref","unstructured":"Alangaden GJ, Wahiduzzaman M, Chandrasekar PH. Aspergillosis: the most common communityacquired pneumonia with gram-negative bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis. 2002;35: 659-664.","DOI":"10.1086\/342061"},{"key":"2020021218361702700_REF41","unstructured":"Walsh TJ, Roden M, Nelson L. Invasive fungal infections complicating non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT). 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Diego, CA: ASM; 2002:abstract M-1233."},{"key":"2020021218361702700_REF42","doi-asserted-by":"crossref","unstructured":"Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis. 2003;36: 9-15.","DOI":"10.1086\/344906"},{"key":"2020021218361702700_REF43","doi-asserted-by":"crossref","unstructured":"Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8: 512-520.","DOI":"10.1053\/bbmt.2002.v8.pm12374456"},{"key":"2020021218361702700_REF44","unstructured":"Marty FM, Lee SJ, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Risk of non-Candida invasive fungal infections in allogeneic bone marrow transplant patients who received infliximab to control severe graft v. host disease. San Diego, CA: ASM; 2002: abstract M-1234."},{"key":"2020021218361702700_REF45","unstructured":"Marty FM, Lee SJ, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Risk of non-Candida invasive fungal infections in allogeneic bone marrow transplant patients who received infliximab to control severe graft v. host disease [abstract]. Blood. 2002;100: 628a."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2768\/1691903\/h82003002768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2768\/1691903\/h82003002768.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:15:47Z","timestamp":1682529347000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/8\/2768\/17711\/Infliximab-use-in-patients-with-severe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,15]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-01-0267","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,15]]}}}